Biodimension raises ₹8 crore in a round led by IAN Angel Fund to accelerate its biofabrication capabilities.
;The startup engineers 3D human tissue and organoid models to replace traditional, error-prone animal testing.
Capital will fund laboratory expansion, product R&D, and commercial growth across India and Southeast Asia.
The company operates a lucrative Bioassay-as-a-Service (BaaS) model, capitalizing on global regulatory shifts toward non-animal drug screening.
Read the full story on StartupFox